Verdinexor (KPT-335) 1392136-43-4

简要描述：Verdinexor (KPT-335) 1392136-43-4
Verdinexor (KPT-335) is an orally bioavailable, selective XPO1/CRM1 inhibitor.

产品咨询联系我们

产品分类

Product Category

查看全部

详细介绍

Verdinexor (KPT-335) 1392136-43-4

产品描述
描述	Verdinexor (KPT-335) is an orally bioavailable, selective XPO1/CRM1 inhibitor.
纯度	98%
储存/保存方法	Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.
基本信息
别名	ATG-527
可溶性/溶解性	DMSO ：88 mg/mL (198.95 mM)
生物活性
靶点	CRM1
In vitro(体外研究)	Verdinexor inhibits the viability of Jurkat, OCI-Ly3, OCI-Ly10, and CLBL1 cells with IC50 of 0.3 nM, 2.1 nM, 41.8 nM, and 8.5 nM, respectively. KPT-335 also induces apoptosis in CLBL1 cells and primary canine DLBCL cells that express XPO1 and SINE. Verdinexor potently and selectively inhibits vRNP export and effectively inhibits the replication of various influenza virus A and B strains, including pandemic H1N1 virus, highly pathogenic H5N1 avian influenza virus, and the recently emerged H7N9 strain.
In vivo(体内研究)	Verdinexor (25 mg/kg twice daily, p.o.) reduces proinflammatory cytokine expression in the lung, produces in vivo antiviral activity by reducing lung virus titers, and thus reduces pulmonary disease pathogenesis and death associated with lethal influenza A virus challenge. In autosomal-dominant polycystic kidney disease model, Verdinexor (5 mg/kg, i.p.) attenuates cyst growth via inhibition of XPO1.

研究领域
研究领域	EpigeneticsDNA / RNARNA ProcessingOther EpigeneticsNuclear Signaling PathwaysNuclear ReceptorsNuclear Pore Complex Signal TransductionProtein TraffickingNuclear Import / Export Drug DiscoverySmall Molecule DrugLead Compound Discovery

Verdinexor (KPT-335) 1392136-43-4温馨提示：本产品仅作科研实验使用，不支持临床等研究

产品咨询